Search

Displaying results 1861 - 1870 of 6949 in total
  1. Drug

    Pivmecillinam

    go.drugbank.com/drugs/DB01605
    ApprovedInvestigational

    It is active against gram-negative organisms and used as for amdinocillin. [PubChem]

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Bicalutamide

    go.drugbank.com/drugs/DB01128
    ApprovedInvestigational

    Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. … Bicalutamide binds to the androgen receptor.

    Categories: Androgen Receptor Antagonists, Androgen Receptor Inhibitors
  3. Drug

    Osimertinib

    go.drugbank.com/drugs/DB09330
    ApprovedInvestigational

    [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved … In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  4. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. … [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.

  5. Drug

    Foreskin keratinocyte (neonatal)

    go.drugbank.com/drugs/DB10772
    Approved

    It is used for grafting onto partial-thickness wounds, where it offers a favorable matrix for host cell migration [L2452]. … A gel made of bovine collagen is used as the matrix for cell growth and differentiation.

  6. Drug

    Rifamycin

    go.drugbank.com/drugs/DB11753
    ApprovedInvestigationalWithdrawn

    [L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801] … Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.

    Categories: Antibiotics for Topical Use, Antiinfectives for Systemic Use
  7. Drug

    Carprofen

    go.drugbank.com/drugs/DB00821
    ApprovedVet approvedWithdrawn

    Carprofen was previously used in human medicine for over 10 years (1985-1995). … It is no longer marketed for human usage, after being withdrawn on commercial grounds.

  8. Drug

    Finasteride

    go.drugbank.com/drugs/DB01216
    ApprovedInvestigational

    the need for surgical procedures. … Finasteride is an orally active drug that was first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and reduce the risk for acute urinary retention or

  9. Drug

    Alfentanil

    go.drugbank.com/drugs/DB00802
    ApprovedIllicitInvestigational

    Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.

  10. Drug

    Rupatadine

    go.drugbank.com/drugs/DB11614
    ApprovedInvestigational

    Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria … It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and liquid formulation for pediatric use.

    Categories: Antihistamines for Systemic Use